Recently RCK, an Israeli cannabis startup company, has signed a multi-million dollar deal with SeedTech of Holland, a pioneer in European cannabis.
The seeds developed by RCK, a company that specializes in science-based cannabis genetics, are aimed to help create global mass production of medicinal cannabis.
The agreement between RCK and SeedTech, a Dutch seed company, are for developing unique cannabis strains in the form of elite hybrid seeds.
RCK’s operations are located in Kibbutz Ruhama, in southern Israel. The company operates a state-of-the-art lab, indoor growing rooms and 1,500 square meters of breeding greenhouse and commercial propagation facility.
As part of the agreement, RCK has devised for SeedTech a dedicated breeding plan to develop unique cannabis strains for medical and commercial uses. In addition to the initial payment for the breeding services, RCK will also receive royalties from the sale of seeds over all the duration of the patent life of each strain.
“The agreement with SeedTech is the byproduct of the pioneering scientific-technological way of thinking that we developed that is now fulfilling its commercial potential,” commented Dr. Noam Chehanovsky, co-founder and VP for R&D at RCK.
“In recent years we focused intensive efforts to crack the genetic makeup of the cannabis plant and we learned to control its chemical compounds. As a result, it is possible to rapidly and efficiently breed new strains that are precisely suitable for various medical or commercial needs and facilitate wide-scale growing of high-quality cannabis plants that meet medical standards.”